Los Angeles Capital Management LLC Sells 37,067 Shares of Altimmune, Inc. (NASDAQ:ALT)

Los Angeles Capital Management LLC lessened its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 35.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,537 shares of the company’s stock after selling 37,067 shares during the period. Los Angeles Capital Management LLC owned 0.09% of Altimmune worth $409,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co bought a new position in shares of Altimmune in the 1st quarter valued at $44,000. TFO Wealth Partners LLC bought a new position in shares of Altimmune in the 1st quarter valued at $51,000. Horizon Wealth Management LLC bought a new position in shares of Altimmune in the 2nd quarter valued at $66,000. PFG Investments LLC bought a new position in shares of Altimmune in the 2nd quarter valued at $67,000. Finally, Principal Financial Group Inc. bought a new position in shares of Altimmune in the 2nd quarter valued at $70,000. Institutional investors own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ALT shares. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Trading Down 9.9 %

Shares of ALT opened at $7.61 on Monday. The company has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. Altimmune, Inc. has a 12 month low of $2.34 and a 12 month high of $14.84. The stock’s 50-day moving average price is $7.02 and its two-hundred day moving average price is $6.91.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the firm posted ($0.39) earnings per share. Equities research analysts predict that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.